Metastasis · People undergoing radiotherapy for uterine cervical cancer
Hyperbaric oxygen showed no clear difference in metastasis compared with air breathing (high certainty).
1 finding from 1 review
Metastases with urinary bladder cancer · People with any one of a mixed group of cancers
Hyperbaric oxygen showed no clear difference in metastases with urinary bladder cancer compared with air breathing (moderate certainty).
1 finding from 1 review
Metastasis · People undergoing radiation therapy for head and neck cancer
Hyperbaric oxygen showed no clear difference in metastasis compared with air breathing to enhance the effectiveness of radiotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
metabolic AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher metabolic AEs (high certainty).
1 finding from 1 review
Intervention not reported
Distant metastasis · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in distant metastasis (moderate certainty).
1 finding from 1 review
Overall survival (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Weight loss (change in kg weight) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Quality of life: FACT‐G (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib may leads to higher overall survival compared with lapatinib (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
1 finding from 1 review